相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lomitapide and Mipomersen Two First-in-Class Drugs for Reducing Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia
Daniel J. Rader et al.
CIRCULATION (2014)
Lack of Clinical Pharmacodynamic and Pharmacokinetic Drug–Drug Interactions Between Warfarin and the Antisense Oligonucleotide Mipomersen
Zhaoyang Li et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-Lowering therapy
Raghu Vishwanath et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management
Jooho Lee et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2014)
Lomitapide: A Review of its Use in Adults with Homozygous Familial Hypercholesterolemia
Caroline M. Perry
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2013)
Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B
Stanley T. Crooke et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2013)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
Gregory S. Thomas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
Marina Cuchel et al.
LANCET (2013)
Homozygous familial hypercholesterolemia (HoFH) in Germany: an epidemiological survey
S. Walzer et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2012)
Lipoprotein(a): more interesting than ever after 50 years
Joseph B. Dube et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
Maartje E. Visser et al.
EUROPEAN HEART JOURNAL (2012)
Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease A Rationale for Increased Efforts to Understand its Pathophysiology and Develop Targeted Therapies
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
Mary P. McGowan et al.
PLOS ONE (2012)
Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
Frederick J. Raal et al.
CIRCULATION (2011)
Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia
Rosanne M. Crooke et al.
CLINICAL LIPIDOLOGY (2011)
Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia
M. E. Visser et al.
DIABETOLOGIA (2011)
ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
Fatima Akdim et al.
EUROPEAN HEART JOURNAL (2011)
Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Stephen R. Daniels et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Paul N. Hopkins et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Michael H. Davidson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice
Adam E. Mullick et al.
JOURNAL OF LIPID RESEARCH (2011)
Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study
Mariana Lazo et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2011)
Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
Fatima Akdim et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
Maartje E. Visser et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
Fatima Akdim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Giovanni Targher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2 '-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Rosie Z. Yu et al.
CLINICAL PHARMACOKINETICS (2009)
Recommendations for the use of LDL apheresis
G. R. Thompson
ATHEROSCLEROSIS (2008)
Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100
Rosie Z. Yu et al.
DRUG METABOLISM AND DISPOSITION (2007)
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Marina Cuchel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Antisense oligonucleotides: The state of the art
T Aboul-Fadl
CURRENT MEDICINAL CHEMISTRY (2005)
Surgical management of dyslipidemia: Clinical and experimental evidence
MH Moghadasian et al.
JOURNAL OF INVESTIGATIVE SURGERY (2001)
Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass
M López-Santamaria et al.
JOURNAL OF PEDIATRIC SURGERY (2000)
Lipoprotein(a) in homozygous familial hypercholesterolemia
HG Kraft et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
分享论文
